PTO Reconsidering Validity Of One Of Pfizer’s Lipitor Patents

Patent & Trademark Office will re-examine whether claims covering the crystalline form of atorvastatin were disclosed in the prior art. The patent runs until January 2017 and is the latest expiring of five Lipitor patents listed in the “Orange Book.”